phyhipl Antibody

What is PHYHIPL and what cellular functions has it been associated with?

PHYHIPL is a mitochondrial protein with a calculated molecular weight of 43 kDa (376 amino acids), though it is commonly observed at 39 kDa and 42-45 kDa in experimental contexts . It is primarily associated with mitochondrial functions including energy production, oxidative stress responses, and organelle dynamics . Recent studies have identified PHYHIPL as a potentially protective gene in glioblastoma multiforme (GBM), where its downregulation correlates with poor patient survival . Protein-protein interaction (PPI) network analysis suggests PHYHIPL plays a vital role in cellular metabolism, potentially regulating mitochondrial function in GBM cells .

PHYHIPL's interaction with phytanoyl-CoA hydroxylase (PHYH) suggests a role in the development of the central nervous system . The protein is encoded by the PHYHIPL gene (ID: 84457), and its expression patterns indicate tissue specificity with high expression in brain and testis tissues .

What experimental applications are PHYHIPL antibodies validated for?

PHYHIPL antibodies have been validated for multiple experimental applications with specific sample types:

The antibodies show reactivity with human, mouse, and rat samples, making them suitable for comparative studies across these species . For optimal results, researchers should perform antibody titration for each specific experimental system to determine the optimal concentration .

What are the recommended storage and handling protocols for PHYHIPL antibodies?

For maximum stability and activity retention, PHYHIPL antibodies should be stored at -20°C . The commercially available antibodies are typically supplied in PBS buffer containing 0.02% sodium azide and 50% glycerol at pH 7.3 . Under these conditions, the antibodies remain stable for one year after shipment .

Important handling considerations include:

• Aliquoting is generally unnecessary for -20°C storage

• Some preparations (e.g., 20μl sizes) may contain 0.1% BSA as a stabilizer

• Avoid repeated freeze-thaw cycles

• Allow the antibody to equilibrate to room temperature before opening the vial

• Centrifuge briefly before use to collect contents at the bottom of the tube

What antigen retrieval methods are recommended for PHYHIPL immunohistochemistry?

For immunohistochemical detection of PHYHIPL in tissue sections, proper antigen retrieval is critical for optimal staining. Based on validated protocols, researchers should consider:

Primary recommendation:

• TE buffer at pH 9.0 for heat-induced epitope retrieval

Alternative method:

• Citrate buffer at pH 6.0 may also be used, though potentially with lower epitope recovery efficiency

The choice between these methods may depend on tissue fixation conditions, section thickness, and co-staining requirements. For mouse brain tissue, which shows reliable PHYHIPL expression, the TE buffer method consistently produces superior results by enhancing antibody accessibility to the epitope while preserving tissue morphology .

How can researchers validate PHYHIPL antibody specificity for their experimental systems?

Validating antibody specificity is critical for reliable research outcomes. For PHYHIPL antibodies, a multi-tiered validation approach is recommended:

• Positive and negative control tissues: Use brain tissue (high expression) as positive control and tissues known to lack PHYHIPL expression as negative controls

• Molecular weight verification: Confirm detection at the expected molecular weights (39 kDa and 42-45 kDa) in Western blot applications

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to eliminate specific binding

• Knockout/knockdown controls: Use PHYHIPL knockout/knockdown samples as negative controls to confirm signal specificity

• Multiple antibody validation: Compare results using antibodies raised against different epitopes of PHYHIPL

• Cross-species reactivity: Verify consistent patterns across human, mouse, and rat samples, accounting for species-specific variations

What is the significance of PHYHIPL in glioblastoma multiforme (GBM) research?

PHYHIPL has emerged as a significant gene in GBM research with potential diagnostic and prognostic value. Analysis of Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) data reveals:

This suggests PHYHIPL functions as a protective gene in GBM development. Bioinformatics analyses indicate that:

• Poor prognosis associated with downregulated PHYHIPL may involve the TNF signaling pathway and the IL-17 signaling pathway

• Favorable prognosis with upregulated PHYHIPL may involve retrograde endocannabinoid signaling and the cAMP signaling pathway

Researchers investigating PHYHIPL in GBM should consider differential expression analysis and survival correlation as primary methodological approaches, followed by pathway analysis to elucidate the mechanisms involved.

What experimental approaches are most effective for studying PHYHIPL in the context of cellular metabolism?

Based on protein-protein interaction (PPI) network analysis, PHYHIPL appears to function in cellular metabolism, particularly in mitochondrial processes . To investigate this role, researchers should consider:

• Mitochondrial fractionation: Isolate mitochondria from brain tissue or neuronal cell cultures to assess PHYHIPL localization and interactions

• Metabolic flux analysis: Measure changes in metabolic parameters following PHYHIPL knockdown/overexpression

• Seahorse assays: Quantify oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) to assess mitochondrial respiration and glycolysis in relation to PHYHIPL expression

• Co-immunoprecipitation: Identify PHYHIPL's interaction partners within the mitochondrial proteome

• Live-cell imaging: Track mitochondrial dynamics and morphology using fluorescently tagged PHYHIPL

Understanding PHYHIPL's role in cellular metabolism could provide insights into its protective function in GBM and potentially reveal therapeutic opportunities targeting metabolic vulnerabilities in GBM cells .

What are the known technical challenges when using PHYHIPL antibodies and how can they be addressed?

Researchers using PHYHIPL antibodies may encounter several technical challenges that require specific troubleshooting approaches:

• Multiple band detection: The observation of bands at both 39 kDa and 42-45 kDa in Western blot may represent:

  • Different isoforms or splice variants

  • Post-translational modifications

  • Partial degradation products

  Solution: Use appropriate positive controls and potentially supplement with mass spectrometry or RNA-seq data to confirm identity of specific bands.

• Cross-reactivity with PHYHIP: Some antibodies recognize both PHYHIP (35-38 kDa) and PHYHIPL (43-45 kDa) .

  Solution: When studying either protein specifically, verify antibody specificity and consider using antibodies raised against non-homologous regions.

• Low signal in certain tissues: While PHYHIPL is expressed in brain tissue, detection in other tissues may require optimization.

  Solution: Adjust antibody concentration, incubation time, and detection system sensitivity. For IHC, optimize antigen retrieval methods.

• Background staining: Non-specific binding can complicate interpretation.

  Solution: Include blocking steps with proper BSA or serum, optimize antibody dilution, and include appropriate negative controls.

What molecular techniques complement antibody-based detection of PHYHIPL?

For comprehensive characterization of PHYHIPL in research settings, antibody-based methods should be supplemented with:

• RT-qPCR: Quantify PHYHIPL mRNA expression with primers targeting exon junctions to distinguish splice variants

• RNA-seq: Analyze transcriptome-wide expression patterns in relation to PHYHIPL

• CRISPR-Cas9 gene editing: Generate PHYHIPL knockout or knock-in models to study function

• Proteomics: Use mass spectrometry to identify PHYHIPL in complex protein mixtures and characterize post-translational modifications

• In situ hybridization: Visualize PHYHIPL mRNA distribution in tissue sections to complement protein localization studies

This multi-modal approach provides validation across different biological levels (genomic, transcriptomic, and proteomic) and strengthens the reliability of research findings.

What are the potential mechanisms underlying PHYHIPL downregulation in glioblastoma?

Current research suggests several potential mechanisms for PHYHIPL downregulation in GBM that warrant further investigation:

• Mutations in β-catenin gene: Evidence suggests β-catenin mutations may influence PHYHIPL expression

• Endogenous siRNA regulation: PHYHIPL has been identified as a potential target of endogenous siRNA derived from RMRP (RNA component of mitochondrial RNA processing endoribonuclease)

• Epigenetic silencing: Hypermethylation of the PHYHIPL promoter region may contribute to reduced expression

• miRNA-mediated regulation: microRNAs upregulated in GBM may target PHYHIPL mRNA

• Altered transcription factor activity: Changes in the activity of transcription factors that regulate PHYHIPL expression

Researchers investigating these mechanisms should consider employing methylation analysis, ChIP-seq for histone modifications, miRNA profiling, and promoter activity assays to comprehensively characterize the regulatory landscape of PHYHIPL in GBM .

How does PHYHIPL interact with cellular signaling pathways in normal and pathological conditions?

Bioinformatics analysis of PHYHIPL's role in cellular signaling pathways reveals interesting associations that deserve experimental validation:

• TNF and IL-17 signaling pathways: These pathways appear to be associated with PHYHIPL downregulation and poor prognosis in GBM

• Retrograde endocannabinoid signaling and cAMP signaling: These pathways are associated with PHYHIPL upregulation and better prognosis

• Mitochondrial signaling networks: As a mitochondrial protein, PHYHIPL likely participates in signaling cascades related to cellular stress responses and energy homeostasis

To investigate these interactions, researchers should consider:

• Pathway inhibitor studies to assess PHYHIPL expression changes

• Co-immunoprecipitation followed by mass spectrometry to identify signaling proteins that interact with PHYHIPL

• Phosphoproteomic analysis to identify signaling-dependent post-translational modifications of PHYHIPL

• Reporter assays to determine how PHYHIPL affects the activity of relevant signaling pathways